Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 ...
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Medicinalselskabet Novo Nordisk overgik markedets forventninger med et overskud på 101 milliarder sidste år. Og analytikere ...
Nu svarer Novo-chefer på spørgsmål fra analytikere – følg med live her window.addEventListener('message', (event) => { if ...
Novo Nordisk øger salg 25 pct. – selv skeptiker spår optur – følg med live her window.addEventListener('message', (event) => ...
Netop derfor holder investorerne vejret frem mod årsregnskabet, der lander onsdag morgen. Som altid vil den fremadrettede prognose være i fokus, mens vægttabshåbet Cagrisema også vil tage kæmpe fokus.
Ideologiske uenigheder og modstridende strategiske interesser kan springe frem, når topministrene tager hul på de første ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results